|
30/04/2010 - Genkyotex completed release of phase I API clinical batch of GKT137831.
Genkyotex announced today having completed release of a first GMP clinical batch of 18Kg of its first-in-class Nox4/Nox1 dual inhibitor GKT137831. “We have achieved successfully an important step of compound development on a very short period of time”. “We benefit of the high quality of the work performed by Genkyotex team on the identification and selection of internally developed candidate drug. We always reached milestones in due time in the past; this additional milestone validates once more our refined and pragmatic industry pharma approach” said Patrick Page, General Manager and CSO of Genkyotex.
26/01/2010 - GenKyoTex annonced today having elected its first candidate drug GKT137831 following completion of lead optimisation and early safety toxicity package. GKT137831 is an internally discovered first-in-class small molecule Nox4/Nox1 dual inhibitor with large safety window. GKT137831 demonstrates strong anti-fibrotic activity at low dose with much better efficacy than Pirfenidone in curative model of bleomycine-induced pulmonary fibrosis in mice. Genkyotex expects to complete regulatory preclinical package and IND approval in Q4 2010 followed by phase I clinical trials starting in late 2010. GKT137831 will be initially developed for fibrotic diseases.
25/09/2009 - GenKyoTex front-runner patents reached national/regional phase stages.
Genkyotex announced having filed regional and national phases for its early patents of Nox4 inhibitors. The patents were filed in all major markets covering Europe, US, Asia, South-America and Australia for a large panel of therapeutic indications. "Developing a strong and aggressive IP strategy is key for the company" said Patrick Page, General Manager and CSO of the Biotech company. "Since its birth in Feb. 2006, we have filed 7 small molecules patents covering several chemical series of Nox inhibitors, this is a great and highly important achievement for the company. This also highlights our capability and commitment to innovation."
15/09/2009 - GenKyoTex reached milestones of completion of lead optimization according to its development plan and starts generation of preclinical development package of first-in-class Nox4 inhibitors. Genkyotex is developing its innovative therapeutics for the treatment of idiopathic pulmonary fibrosis and metastatic renal cancer. The biotech company demonstrated recently tremendous results with its Nox4 inhibitors in in vivo pharmacological models of pulmonary fibrosis.
15/05/2009 - GenKyoTex raises a CHF 2Millions through the FAE (Canton de Genéve) to complete Series A fund. This strategic investment will allow the biotech company to further achieve preclinical development of its first in class NADPH Oxidase isoform 4 (Nox4) inhibitors that demonstrate highly promising potential for the treatment of Idiopathic Pulmonary Fibrosis (IPF, orphan disease) and metastatic renal cancer.
05/05/2008 - GenKyoTex Raises a CHF 4Millions Series A fund for Preclinical Development of first in class NADPH Oxidase inhibitors for the treatment of Renal cancer, Idiopathic Pulmonary Fibrosis (IPF), atherosclerosis and diabetic nephropathy
16/10/2007 - GenKyoTex awarded the CTI start-up Label by the Swiss Federal Office for Professional Education and Technology.
|
Calendar of events
